INTRODUCTION
The New York Academic Consortium (NYAC) is comprised of the licensing and business development offices of the seven largest biomedical institutions in New York City. NYAC offices work together, to develop and share the best practices that have made NYC one of the leading sources of pharmaceutical and biotechnology products and innovation. Collectively, our offices have achieved extraordinary results in commercializing the discoveries of their distinguished faculties, whether through direct licensing to pharma and biotech, or the formation of new startup companies. For more information on finding your firm’s next success story, please contact any of our member offices.

ALBERT EINSTEIN COLLEGE OF MEDICINE
Offices of Biotechnology and Business Development
1300 Morris Park Avenue
Bronx, NY 10461
T. 718.430.3357
F. 718.430.8938
Email: www.einstein.yu.edu/biotechnology

Albert Einstein College of Medicine of Yeshiva University is one of the nation's premier centers for research, medical education, and clinical investigation. The College of Medicine has an extensive affiliation network involving seven medical centers in the Bronx, Manhattan, Brooklyn, and Long Island, which includes Montefiore Medical Center, the University Hospital and academic medical center for Einstein.

In 2011, Einstein received nearly $170 million in awards from the NIH. This includes the funding of major research centers at Einstein in diabetes, cancer, liver disease, and AIDS. Other areas where the College of Medicine is concentrating its efforts include developmental brain research, neuroscience, cardiac disease, and initiatives to reduce and eliminate ethnic and racial health disparities.

Einstein’s Offices of Biotechnology and Business Development work together to fulfill the mission of assisting the translation of basic research advances made at Einstein into clinical applications that can benefit the public.

COLUMBIA UNIVERSITY
Columbia Technology Ventures
80 Claremont Avenue, Suite 4F
New York, NY 10032
T. 212.854.8444
F. 212.854.8463
www.techventures.columbia.edu
techventures@columbia.edu

Columbia University is widely recognized and respected as a leading source of new scientific knowledge and innovation. With research expenditures in excess of $800 million, Columbia generates 300+ new inventions, 50+ new licenses, and 15+ new startup companies each year.

Columbia Technology Ventures manages Columbia’s intellectual property portfolio and serves as the University's gateway for companies and entrepreneurs seeking novel technology solutions and opportunities.

Since the founding of our office in 1982, Columbia inventions have contributed to advances in a wide range of fields and markets, resulting in hundreds of products and services that touch the daily lives of people all over the world. Our success is due to an exceptional base of world-class scientists working in diverse and dynamic areas of science and engineering.

CORNELL CENTER FOR TECHNOLOGY ENTERPRISE AND COMMERCIALIZATION
Weill Cornell Medical College
418 E. 71st Street, Suite 61
New York, NY 10021
T. 212.746.6186
F. 212.746.6662
www.cctec.cornell.edu

The mission of the New York Office of the Cornell Center for Technology Enterprise and Commercialization (CCTEC) is to partner with industry to develop the technologies developed at Weill Cornell Medical College (WCMC) into products and services for the public good. The mission also includes providing technology transfer services to WCMC faculty and researchers, and leveraging Cornell’s innovation to promote entrepreneurial opportunities and regional economic development.

Each year the New York CCTEC office hosts several events to outreach to both the WCMC faculty and to the industrial and financial community who might be interested in Cornell technology. These include IP and Pizza to educate WCMC faculty on what constitutes intellectual property and how Cornell manages it, and Inventions Roundtable to present emerging technologies with application to a specific field to relevant industry and venture investors.

Anyone interested in receiving CCTEC’s newsletter, attending its events, or participating in its Industry Advisors Group, which helps CCTEC determine the commercial potential and strategy of Cornell inventions, should contact us at cctec-connect@cornell.edu.

NYAC STATISTICS
Annual Research Funds $2.3 billion [FY2010]
Number of Inventions/Disclosures 848
MEMORIAL SLOAN-KETTERING CANCER CENTER
Office of Technology Development
1275 York Avenue
New York, NY 10021
T. 212.639.6181
F. 212.717.3439
www.mskcc.org/otd

The Office of Technology Development (OTD) works together with colleagues throughout Memorial Sloan-Kettering Cancer Center (MSKCC) to support its overall mission: To achieve the progressive control and cure of cancer through programs of patient care, research, and education.

MSKCC’s world-renowned researchers have produced important new technologies in the fields of therapeutics, diagnostics, medical devices, research tools, and vaccines. With a strong commitment to translational research, Memorial Sloan-Kettering Cancer Center and its Office of Technology Development have been involved with the development of nine FDA-approved drugs and the first USDA-approved therapeutic canine vaccine for the treatment of cancer. These are unparalleled achievements for an institution of its size.

OTD has recently launched a New Ventures & Business Development initiative to serve as a resource for MSKCC researchers interested in exploring entrepreneurial opportunities relating to their technological developments. OTD’s licensing team is committed to working closely with life sciences corporations, venture capitalists, and angel investors to develop MSKCC innovation.

MOUNT SINAI SCHOOL OF MEDICINE
Office of Technology and Business Development
1 Gustave L. Levy Place, Box 1675
New York, NY 10029
T. 212.659.9680
F. 212.348.3116
www.mssm.edu/otbd

The Office of Technology and Business Development (OTBD), as part of The Mount Sinai School of Medicine (MSSM), facilitates the transfer of discovery from the laboratory to the marketplace, acting as the interface with commercial entities.

OTBD is responsible for the full spectrum of commercialization activities required to bring MSSM’s inventions to life. These activities include evaluating, patenting, marketing, and licensing new technologies, while also negotiating various agreements for sponsored research, material transfer, and confidentiality. Through Blue Mountain Technologies, OTBD also utilizes MSSM’s growing portfolio of molecular diagnostic reagents to assist partners with advancing research and commercialization.

The Office plays a significant role in alliance management to ensure MSSM and its partners are continuously meeting their goals. OTBD has managed industry relationships that have resulted in numerous products to address patient needs (including more than 15 technologies in preclinical or clinical development) and 11 companies based on MSSM technologies.

MSSM’s dedication to OTBD through investment supports our innovative faculty and continues to strengthen connections with industry.

NEW YORK UNIVERSITY
Office of Industrial Liaison
One Park Avenue, 6th floor
New York, NY 10016-5802
T. 212.263.8178
F. 212.263.8189
www.nyu.edu/oil

The mission of the NYU Office of Industrial Liaison is to promote the commercial development of NYU technologies into products to benefit the public. Twenty-four products have come to market based on NYU technologies, including the drugs Remicade and Sutent, medical devices, diagnostics, and electronics. Numerous additional products are under development by NYU licensees.

The Office actively seeks commercial partners to develop NYU technologies, and works to establish mutually beneficial long-term relationships. Almost 60% of NYU patents have been licensed to companies for development and commercialization. Over the past five years, NYU has ranked first among all U.S. universities in income from technology licensing, which is plowed back into further research.

NYU actively promotes entrepreneurship with 70 companies created based on NYU technologies. We encourage companies, venture investors, and entrepreneurs to contact us to explore how we can work together developing new technologies and creating new ventures to benefit the public.

THE ROCKEFELLER UNIVERSITY
Office of Technology Transfer
1200 York Avenue, Box 138
New York, NY 10065
T. 212.327.8266
F. 212.327.8267

The Rockefeller University was founded in 1901 as the nation’s first institute for medical research. Since then, scientists at Rockefeller have made numerous fundamental contributions to the advancement of biomedical knowledge, including the discovery that DNA is the basic material of heredity, cancer can be caused by a virus, confirming the connection between cholesterol and heart disease, developing methadone maintenance for heroin addicts, and developing the AIDS cocktail drug therapy.

Rockefeller has dedicated its second century to translating the insights gained from advances in genomics and molecular biology to improve human health. The Office of Technology Transfer facilitates the protection and further development of technologies and innovations discovered by personnel of the University. Patentable inventions, tangible materials, and copyrighted materials are transferred to the for-profit sector for further development into useful commercial products and services. We actively seek partnerships with companies of all sizes as well as entrepreneurs seeking to establish new companies.

NYAC STATISTICS
Active Revenue Generating Agreements 575
Gross Licensing Revenue $484 million
New Startup Companies 33